MedTrace Logo

Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia

NCT02918825 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-01-18

No results posted yet for this study

Summary

A randomized trial of olanzapine and Long-acting paliperidone palmitate injection in the treatment of 100 treatment- naive first-episode patients with schizophrenia.

Conditions

Interventions

DRUG

Olanzapine

Olanzapine

DRUG

Paliperidone

Paliperidone

Sponsors & Collaborators

  • Beijing HuiLongGuan Hospital

    lead OTHER

Principal Investigators

  • Xiang Zhang, MD, PhD · The University of Texas Health Science Center, Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-01
Primary Completion
2017-08-30
Completion
2017-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02918825 on ClinicalTrials.gov